AlphAIAlphAI — Financial news for AI agents
investing.com$PGNY

Progyny earnings beat, revenue topped estimates

Progyny (PGNY) reported Q3 EPS of $0.32, beating estimates of $0.31, with revenue at $341.25M, slightly above the $340.76M consensus. The stock is up 7.12% over 3 months and 59.43% over 12 months. InvestingPro rates its financial health as 'great performance'.

Original reporting
investing.com
Published Nov 5, 2026, 12:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PGNY
Bullish
high confidence
Mentioned
$PGNY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PGNYBullishHigh
01

Why it matters

The earnings beat may trigger short covering and buying interest, especially after a strong 12‑month rally.

02

Market read

Earnings beat is a primary catalyst for PGNY and may influence related HR‑tech stocks.

03

What to watch

Guidance outlook and cash flow details were not disclosed, which could temper upside.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

Progyny is a cloud‑based benefits platform; its earnings release provides fresh performance data.

Company-level read

Ticker impact

$PGNYBullishHigh confidence
Context

Progyny reported Q3 EPS of $0.32 beating the $0.31 estimate and revenue of $341.25M beating the $340.76M consensus.

Expected impact

likely upward pressure as investors price in the earnings beat

Evidence & confidence

The beat on both earnings and revenue is fresh data that can move the share price in the near term.

Market effects

Sector

Positive for the employee benefits/HR tech sector as a beat may lift peers.

Regional

U.S. market sentiment may improve modestly in the health‑benefits niche.

Global

Limited to U.S. investors; no broader macro effect.

Counterpoint

What could challenge this read

If the beat was driven by one‑off items, the stock could face a pull‑back.

Key entities

  • Company
    Progyny

    Provider of employee benefits solutions, ticker PGNY.

Read at source← All news

StoryProgyny reports third-quarter revenue growth and raises full-year guidance

Also covered by

3 outlets

Related articles

$PGNYMed

Progyny (PGNY) Q3 2026 Earnings Call Transcript

Progyny (PGNY) reported record revenue and profitability for Q3 2026, with strong cash flow used for growth and share repurchases. The company added 1.3M new covered lives and 85 new clients, raising full-year guidance. Management highlighted strong demand for family building and women's health benefits, diverse client base, and market differentiation. Retention was near 100%, with 20% of clients expanding services. Progyny Select, a new offering, is expected to contribute to long-term growth.

finance.yahoo.com
$PGNYMedAI 8/10

Progyny 3Q 2026: Revenue $341.25M, EPS $0.32 — 10-Q Summary

Progyny reported 3Q 2026 revenue of $341.25M, up 8.9% YoY, and net income of $26.25M, up 89.4% YoY. Growth was driven by increased client and covered-life counts, improving gross margin to 24.5%. Fertility benefits and Progyny Rx revenue rose 11% and 6%, respectively. The company served 607 clients and 7.155M members as of September 30, 2026.

tradingview.com
$PGNYHigh

Progyny Q3 Earnings Call Highlights

Progyny (PGNY) reported Q3 earnings, highlighting a 130 basis point gross margin expansion and $56M in operating cash flow. CEO Anevski noted high client attach rates for Progyny Rx and expects 3M lives to access expanded products by 2027. The company repurchased 3M shares for $83M and plans to taper investments in 2027.

finance.yahoo.com